RxDoctor Payments Data

Johanna Godoy, DPM

Foot & Ankle Surgery · Wayne, NJNPI 1528220084

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $189,650 of the $253,608 with a category attached, or 74.8%. Stryker accounts for 85.4% of it on its own, with 38 other manufacturers making up the rest. Reporting peaked in 2023 at $84,645 and has fallen 58.7% since, to $34,968 in 2025. Among foot & ankle surgery clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$253,608in general payments, 2019–2025

Across 488 payments — averaging $519.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$217K
  • DNE LLC$13K
  • Seapearl East, Inc$6K
  • Paragon 28, Inc.$6K
  • Kerecis Limited$4K
  • Arthrex$4K
  • plus $5K from 33 others

What the payments were for

  • Consulting fees$189,65075%
  • Travel & lodging$38,34015%
  • Food & beverage$19,1948%
  • Education$6,4243%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$253,608 in reported general payments places this provider in the 95th percentile of 542 foot & ankle surgery providers in New Jersey.

See all foot & ankle surgery providers in New Jersey

Medicare billing

Part B allowed, 2024
$84,263
Medicare patients
279
Services billed
1,006

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.11$3,326
CiclopiroxCiclopirox Olamine44$1,589
Ammonium Lactate11$195
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim17$119
Ibuprofen22$67

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$276$3,32611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 542 foot & ankle surgery providers in New Jersey.

Other foot & ankle surgery in Wayne

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →